$599

Lilly Interim Heart-2 Results; Ionis Q6M sHTG Study; CNPV Program Future; Biosimilar Lantus Approval

A series of cardiometabolic-related news items has been observed from Lilly, Ionis, FDA, and Lannett. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here